Treatment of refractory chronic daily headache with the atypical antipsychotic ziprasidone - A case series

Cephalalgia

Volumn 25, Issue 10, 2005, Pages 822-826

  Cahill, C M ^a   Hardiman, O ^a   Murphy, K C ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CAFFEINE; CARBAMAZEPINE; CITALOPRAM; CODEINE PHOSPHATE; DICLOFENAC; FLUOXETINE; GABAPENTIN; IBUPROFEN; INDOMETACIN; METOPROLOL; PARACETAMOL; PIZOTIFEN; REBOXETINE; SOLPADEINE; TIZANIDINE; TRAMADOL; VENLAFAXINE; ZIPRASIDONE;

ADULT; ANAMNESIS; ARTICLE; BECK DEPRESSION INVENTORY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DRUG INDUCED HEADACHE; FEMALE; HEADACHE; HUMAN; MEDICAL SOCIETY; MIGRAINE WITH AURA; NAUSEA; NEUROLOGIC EXAMINATION; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHOBIA; PHONOPHOBIA; PHYSICAL ACTIVITY; PHYSIOTHERAPY; SCOTOMA; SEDATION; SIDE EFFECT; VISUAL IMPAIRMENT;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HEADACHE DISORDERS; HUMANS; MIDDLE AGED; PIPERAZINES; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 25444463036     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.00947.x     Document Type: Article

References (32)

1. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep 2001; 5:529-36.
2. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders (2nd edition). Cephalalgia 2004; 24 (Suppl. 1):8-160.
3. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use? Headache 2003; 43:179-90.
4. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3:475-83.
5. Lu SR, Fuh JL, Juang KD, Wang SJ. Repetitive intravenous prochlorperazine treatment of patients with refractory chronic daily headache. Headache 2000; 40:724-9.
6. Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache 1997; 22:377-82.
7. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002; 42:515-8.
8. Diagnostic and statistical manual of mental disorders, 4th edn. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
9. Beck AT, Brown GK, Steer RA. Beck Depression Inventory-II (BDI-II). San Antonio, TX: The Psychological Corporation, 1996.
10. Pfizer Ireland. Geodon (ziprasidone HCL). Summary of product characteristics. February 2002.
11. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275:101-13.
12. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002; 36:839-51.
13. Welch KMA. Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci 2003; 24:5149-5153.
14. Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia 1998; 18:174-82.
15. Peroutka SJ, Price SC, Wilhoit TL, Jones KW. Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Mol Med 1998; 4:14-21.
16. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med 2002; 23:141-8.
17. Sharma S, Prasad A, Nehru R, Anand KS, Rishi RK, Chaturvedi S et al. Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. Headache 2002; 42:896-902.
18. Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: a randomized, double blind, placebo-controlled trial. Neurology 2003; 60:315-21.
19. Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedebergs Arch Pharmacol 1994; 350:225-9.
20. Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H. Activation of meningeal 5-HT2b receptors: an early step in the generation of migraine headache? Eur J Neurosci 1996; 8:959-67.
21. Kalkman HO. Is migraine prophylactic activity caused by 5-HT2B or 5-HT2C blockade? Life Sci 1994; 54:641-1.
22. 2A receptor activation and nitric oxide synthesis: a possible mechanism determining migraine attacks. Headache 2002; 42:566-74.
23. Srikatkhachorn A, Puangniyom S, Govitrapong P. Plasticity of 5-HT2A serotonin receptor in patients with analgesic-induced transformed migraine. Headache 1998; 38: 534-9.
24. Glennon RA, Dukat M, Westkaemper RB. Serotonin receptor subtypes and ligands. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, American College of Neuropsychopharmacology (ACNP), 2000.
25. Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001; 26:37-43.
26. Pazos A, Hoyer D, Dietl M, Palacios JM. Autoradiography of serotonin receptors. In: Osbourne NN, Hamon M, editors. Neuronal serotonin. London: Wiley, 1988:507-44.
27. Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999; 51:533-91.
28. Eide PK, Hole K. The role of 5-hydroxytryptamine (5-HT) receptor subtypes and plasticity in the 5-HT systems in the regulation of nociceptive sensitivity. Cephalalgia 1993; 13:75-85.
29. Cassidy EM, Tomkins E, Sharifi N, Dinan T, Hardiman O, O'Keane V. Differing central amine receptor sensitivity in different migraine subtypes? A neuroendocrine study using buspirone. Pain 2003; 101:283-90.
30. Cassidy EM, Tomkins E, Dinan T, Hardiman O, O'Keane V. Central 5-HT receptor hypersensitivity in migraine without aura. Cephalalgia 2003; 23:29-34.
31. Schmidt AW, Lebel LA, Howard HR, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425:197-201.
32. Daniel DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry 2003; 64 (Suppl. 19):40-9.